Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

• Esther Redondo ^[4] ; Irene Rivero-Calle ^[5] ; Enrique Mascarós ^[6] ; Daniel Ocaña ^[7] ; Isabel Jimeno ^[8] ; Ángel Gil ^[1] ; Manuel Linares ^[9] ; María Ángeles Onieva-García ^[2] ; Fernando González-Romo ^[3] ; José Yuste ^[1] ; Federico Martinón-Torres ^[5]
  1. [1] Instituto de Salud Carlos III

     Instituto de Salud Carlos III

     Madrid, España

     
  2. [2] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  3. [3] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  4. [4] Infectious, Migrant, Vaccines and Preventive Activities Group of SEMERGEN, International Healthcare Centre of the City Council of Madrid, Madrid
  5. [5] Translational Paediatrics and Infectious Diseases Section, Paediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela
  6. [6] Health Department, Hospital la Fe, Primary Care Centre Arquitecto Tolsá, Valencia
  7. [7] Primary Care, Health Care Centre Algeciras, Algeciras
  8. [8] Primary Care Health Centre Isla de Oza, Vaccine Responsible of SEMG, Madrid
  9. [9] Specialist in Primary Care and Clinical Microbiology, Infectious Diseases Group SEMERGEN, Fundación io, Madrid

  Mostrar afiliaciones +
• Localización: Archivos de bronconeumología: Organo oficial de la Sociedad Española de Neumología y Cirugía Torácica SEPAR y la Asociación Latinoamericana de Tórax ( ALAT ), ISSN 0300-2896, Vol. 60, Nº. 3, 2024, págs. 161-170
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in adults, particularly older adults and those with underlying medical conditions. Vaccination has emerged as a potential key strategy to prevent RSV-related morbidity and mortality. This Neumoexperts Prevention (NEP) Group scientific paper aims to provide an evidence-based positioning and RSV vaccination recommendations for adult patients. We review the current literature on RSV burden and vaccine development and availability, emphasising the importance of vaccination in the adult population. According to our interpretation of the data, RSV vaccines should be part of the adult immunisation programme, and an age-based strategy should be preferred over targeting high-risk groups. The effectiveness and efficiency of this practice will depend on the duration of protection and the need for annual or more spaced doses. Our recommendations should help healthcare professionals formulate guidelines and implement effective vaccination programmes for adult patients at risk of RSV infection now that specific vaccines are available.